Literature DB >> 8988177

Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma.

M P Simon1, F Pedeutour, N Sirvent, J Grosgeorge, F Minoletti, J M Coindre, M J Terrier-Lacombe, N Mandahl, R D Craver, N Blin, G Sozzi, C Turc-Carel, K P O'Brien, D Kedra, I Fransson, C Guilbaud, J P Dumanski.   

Abstract

Dermatofibrosarcoma protuberans (DP), an infiltrative skin tumour of intermediate malignancy, presents specific features such as reciprocal translocations t(17;22)(q22;q13) and supernumerary ring chromosomes derived from the t(17;22). In this report, the breakpoints from translocations and rings in DP and its juvenile form, giant cell fibroblastoma (GCF), were characterised on the genomic and RNA level. These rearrangements fuse the platelet-derived growth factor B-chain (PDGFB, c-sis proto-oncogene) and the collagen type I alpha 1 (COL1A1) genes. PDGFB has transforming activity and is a potent mitogen for a number of cell types, but its role in oncogenic processes is not fully understood. COL1A1 is a major constituent of the connective tissue matrix. Neither PDGFB nor COL1A1 have so far been implicated in any tumour translocations. These gene fusions delete exon 1 of PDGFB, and release this growth factor from its normal regulation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8988177     DOI: 10.1038/ng0197-95

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  90 in total

1.  COL1A1-PDGFB fusion transcripts in fibrosarcomatous areas of six dermatofibrosarcomas protuberans.

Authors:  J Wang; Y Morimitsu; S Okamoto; M Hisaoka; T Ishida; W Sheng; H Hashimoto
Journal:  J Mol Diagn       Date:  2000-02       Impact factor: 5.568

2.  Double target for tumor mass destruction.

Authors:  Pipsa Saharinen; Kari Alitalo
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

3.  PDGF-B exploits stromal EPO.

Authors:  Lisa M McGinnis; Calvin J Kuo
Journal:  Nat Med       Date:  2012-01-06       Impact factor: 53.440

Review 4.  Targeted therapy for dermatofibrosarcoma protuberans.

Authors:  Thomas A Abrams; Scott M Schuetze
Journal:  Curr Oncol Rep       Date:  2006-07       Impact factor: 5.075

Review 5.  The platelet-derived growth factor receptor as a therapeutic target.

Authors:  Nancy L Lewis
Journal:  Curr Oncol Rep       Date:  2007-03       Impact factor: 5.075

6.  Molecular basis of differentiation therapy for soft tissue sarcomas.

Authors:  Gaurav Luther; Richard Rames; Eric R Wagner; Gaohui Zhu; Qing Luo; Yang Bi; Stephanie H Kim; Jian-Li Gao; Enyi Huang; Ke Yang; Linyuan Wang; Xing Liu; Mi Li; Ning Hu; Yuxi Su; Xiaoji Luo; Liang Chen; Jinyong Luo; Rex C Haydon; Hue H Luu; Lan Zhou; Tong-Chuan He
Journal:  Trends Cancer Res       Date:  2010

Review 7.  Role of platelet-derived growth factors in physiology and medicine.

Authors:  Johanna Andrae; Radiosa Gallini; Christer Betsholtz
Journal:  Genes Dev       Date:  2008-05-15       Impact factor: 11.361

Review 8.  Selectivity and therapeutic inhibition of kinases: to be or not to be?

Authors:  Kamran Ghoreschi; Arian Laurence; John J O'Shea
Journal:  Nat Immunol       Date:  2009-03-19       Impact factor: 25.606

Review 9.  Gene translocations in musculoskeletal neoplasms.

Authors:  Balaji Krishnan; Gaurav Khanna; Denis Clohisy
Journal:  Clin Orthop Relat Res       Date:  2008-06-20       Impact factor: 4.176

Review 10.  Genomic characteristics of soft tissue sarcomas.

Authors:  Fredrik Mertens; Ioannis Panagopoulos; Nils Mandahl
Journal:  Virchows Arch       Date:  2009-02-03       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.